X4 Pharmaceuticals (XFOR)

• Market cap: $16.3M
• 1 day: -7.54%
• 5 days: -35.91%
• 1 month: -14.80%
• 3 months: -70.32%
• 6 months: -85.98%
• Year to date: -87.50%
• 1 year: -91.13%
• 5 years: -98.93%
• 10 years: -99.33%
• Sector: Healthcare
• Industry: Biotechnology

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

552% more call options, than puts

Call options by funds: $202K | Put options by funds: $31K

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

4% more funds holding

Funds holding: 90 [Q4 2024] → 94 (+4) [Q1 2025]

1.75% less ownership

Funds ownership: 58.53% [Q4 2024] → 56.78% (-1.75%) [Q1 2025]

68% less capital invested

Capital invested by funds: $73.2M [Q4 2024] → $23.6M (-$49.7M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 148% upside
• Avg. target: $49 1,620% upside
• High target: $90 3,091% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth	148% upside $7	Buy Maintained	2 May 2025
Cantor Fitzgerald Kristen Kluska	3,091% upside $90	Overweight Reiterated	26 Mar 2025